Adimab forms therapeutic discovery partnership with Innovent Biologics
Also receives milestone payments from existing collaborators including Eli Lilly and Kyowa Hakko Kirin
Adimab, a US specialist in the discovery of monoclonal and bispecific antibodies, has formed a partnership with Innovent Biologics, a Chinese antibody therapeutics and manufacturing company funded by Fidelity and Eli Lilly in the US, for the discovery, development and commercialisation of an antibody-based therapeutic programme.
Under the terms of the agreement, Adimab will identify a fully human therapeutic antibody against a target selected by Innovent. All initial product development, including manufacturing and clinical trials, will be coordinated by Innovent. Both companies will retain the rights to develop and commercialise a therapeutic programme in the US, Europe and Japan in the case of Adimab and in China for Innovent.
Adimab has also received undisclosed technical milestone payments from its ongoing collaborations with Eli Lilly, Gilead and Kyowa Hakko Kirin.
Over the past four years, Adimab has established partnerships with Merck, Roche, Novartis, Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK. These partnerships range from single target funded discovery projects, to larger multi-target funded discovery collaborations, as well as full transfer and enablement of the Adimab Platform to pharmaceutical companies. These collaborations focus on IgG discovery, optimisation, humanisation and/or bispecifics for therapeutic products.